To the best of our knowledge, this is the first report on the efficacy of treatment with an anti-PD-1 antibody in a patient with MSI-H cholangiocarcinoma after the failure of the anti-PD-L1 antibody treatment. Here, PDCD1 is linked to cholangiocarcinoma.